Gevokizumab ELISA Kit

Gevokizumab (XOMA-052) was developed by XOMA Ltd., USA and represents a humanized IgG2kappa antibody. XOMA-052 binds to IL-1β with high affinity leading to reduced binding affinity of the cytokine to its signaling receptor. Since gevokizumab does not influence the affinity of IL-1β for its decoy and soluble inhibitory receptors the endogenous regulatory mechanisms involving the clearance and inhibitory receptors also contribute to the effect of the antibody [6]. In August 2012 the FDA granted orphan drug status to gevokizumab for the treatment of noninfectious intermediate uveitis, posterior uveitis, panuveitis, and chronic noninfectious anterior uveitis. A single intravenous injection of the substance was also shown to lead to complete resolution of intraocular inflammation in Behçet’s uveitis.

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.